SciClone Pharmaceuticals Inc. announced presentations of multiple abstracts demonstrating SCV-07's anti-tumor immunomodulating properties at two upcoming events: Cold Spring Harbor Laboratory's Harnessing Immunity to Prevent and Treat Disease meeting; and the American Association for Cancer Research (AACR), National Cancer Institute (NCI), and European Organization for Research and Treatment of Cancer (EORTC)'s Molecular Targets and Cancer Therapeutics International Conference. The presentations include data on SCV-07's role as a breast cancer adjuvant, its efficacy in treating B16 melanoma, and its effect on STAT3-related immune responses. SCV-07 (gamma-D-glutamyl-L-tryptophan) is a small molecule which stimulates the immune system through inhibition of STAT3 signaling and the resulting effects on T-helper 1 cells. SCV-07 has been shown to be efficacious in animal models of immune-sensitive diseases, including viral infections and cancers, and in the enhancement of response to vaccines. The compound has demonstrated an ability, for example, to reduce progression of renal and lung carcinoma as well as melanoma in mouse models. Additionally, SciClone is conducting a phase 2 multicenter, randomized, double-blind, placebo-controlled, dose ranging study, designed to assess the safety and efficacy of SCV-07 for the delay to onset and severity of severe oral mucositis in patients receiving standard chemoradiation therapy for treatment of cancers of the head and neck. SciClone expects to complete enrollment in this study in the second half of 2009 and provide initial results in the first half of 2010.

SciClone Pharmaceuticals Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported income from operations of $2,279,000, income before provision for income tax of $2,226,000, net income of $2,064,000 or $0.04 diluted per share on product sales of $17,240,000 against income from operations of $743,000, income before provision for income tax of $812,000, net income of $773,000 or $0.02 diluted per share on product sales of $14,328,000 for the same period a year ago. According to Non-GAAP, the company reported a net income of $2,493,000 or $0.05 diluted per share against a net income of $1,195,000 or $0.03 diluted per share for the same period a year ago. For the nine months, the company reported income from operations of $9,998,000, income before provision for income tax of $9,973,000, net income of $9,499,000 or $0.20 diluted per share on product sales of $54,280,000 against loss from operations of $5,372,000, loss before provision for income tax of $4,864,000, net loss of $5,205,000 or $0.11 diluted loss per share on product sales of $38,796,000 for the same period a year ago. According to Non-GAAP, the company reported a net income of $10,805,000 or $0.23 diluted per share against a net loss of $3,791,000 or $0.08 diluted loss per share for the same period a year ago. Revenues for the full year 2009 between $70 and $72 million, an increase of approximately 29% to 33% over 2008. Earnings per share for the full year 2009 between $0.18 and $0.22.

To present a corporate overview and business update